The Prevention of Prostate Cancer — The Dilemma Continues
- 17 July 2003
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 349 (3) , 297-299
- https://doi.org/10.1056/nejme038109
Abstract
Prostate cancer is the most common non-skin cancer in the United States, the second leading cause of death from cancer among U.S. men, and the seventh leading cause of death in the United States. The number of new cases of prostate cancer, now estimated at more than 220,000 per year, is expected to increase to more than 380,000 by 2025 because of the aging male population. The incidence of prostate cancer and the rate of death due to the disease increase exponentially with age. The other major risk factors for prostate cancer include a family history of prostate cancer, black . . .Keywords
This publication has 12 references indexed in Scilit:
- The Influence of Finasteride on the Development of Prostate CancerNew England Journal of Medicine, 2003
- Pathologic features of prostate cancer found at population-based screening with a four-year interval.JNCI Journal of the National Cancer Institute, 2001
- Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy?Urology, 1999
- Competing Risk Analysis of Men Aged 55 to 74 Years at Diagnosis Managed Conservatively for Clinically Localized Prostate CancerJAMA, 1998
- Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trialUrology, 1998
- The Effect of Finasteride on the Risk of Acute Urinary Retention and the Need for Surgical Treatment among Men with Benign Prostatic HyperplasiaNew England Journal of Medicine, 1998
- The early detection of prostate carcinoma with prostate specific antigenCancer, 1997
- Occult prostate cancer in men with low serum testosterone levelsPublished by American Medical Association (AMA) ,1996
- Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Investigate the Effect of Finasteride (MK-906) on Stage D Prostate CancerJournal of Urology, 1992
- Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate diseaseJAMA, 1992